

Our ref: IG/FOI/FOI.042.26

11 February 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

## Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 30 January 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

### Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information:

Q1. Does your Trust treat patients for the two following conditions?

Yes/No

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)

If yes:

Q1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

Waldenström macroglobulinaemia (WM)

Marginal zone lymphoma (MZL)

Q1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

Waldenström macroglobulinaemia (WM)  
 Marginal zone lymphoma (MZL)

Please skip 1c to question 2 and 3.

If no:

Q1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

Q2. How many patients (and new patients\* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

| Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)         |                |               |
|--|----------------|---------------|
| Regimen  | Total Patients | New Patients* |
| Fludarabine, cyclophosphamide and rituximab (Known as FCR) |                |               |
| Bendamustine in combination with rituximab (Known as BR)   |                |               |
| Ibrutinib  |                |               |
| Ibrutinib in combination with rituximab                    |                |               |
| Zanubrutinib   |                |               |
| Acalabrutinib  |                |               |
| Chemotherapy (Other than the listed regimens)              |                |               |
| Wait and watch - no active treatment and monitoring only   |                |               |
| Any other treatment (Other than the listed regimens)       |                |               |

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

Q3. How many patients (and new patients\* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

| Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)                              |                |               |
|--|----------------|---------------|
| Regimen  | Total Patients | New Patients* |
| Bendamustine in combination with rituximab (Known as BR)                         |                |               |
| Chlorambucil in combination with rituximab (Known as CR)                         |                |               |
| R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)                |                |               |
| R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) |                |               |
| Zanubrutinib   |                |               |

|  |  |  |
|--|--|--|
| Stem Cell Transplant                                     |  |  |
| Wait and watch - no active treatment and monitoring only |  |  |
| Any other treatment (Other than the listed regimens)     |  |  |

\*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

Powys Response:

Powys Teaching Health Board (PTHB) does not initiate treatment for the two conditions listed; patients are treated by providers outside of Powys. I can also confirm that there are no ongoing clinical trials for either condition. PTHB commissions oncology services from several Welsh health boards and English provider organisations.

Due to the complex nature of PTHB's commissioning arrangements, not all of our providers indicate the indication for use for each episode of care where these drugs are used. For this reason, PTHB does not hold the data relating to your request, however, the health board is working closely with providers to ensure that this information can be provided in the future.

We therefore recommend that you approach our providers for this information directly:

| <b>Health Trust/Organisation</b>                     | <b>FOI Contact Details</b>         |
|--|------------------------------------|
| Gloucestershire Hospitals NHS Foundation Trust       | ghn-tr.foi@nhs.net                 |
| Midlands Partnership University NHS Foundation Trust | FOI@mpft.nhs.uk                    |
| Sandwell and West Birmingham NHS Trust               | swb-tr.SWBH-GM-FOIRequests@nhs.net |
| The Shrewsbury and Telford Hospital NHS Trust        | sath.foi@nhs.net                   |
| The Royal Wolverhampton NHS Trust                    | rwh-tr.foi@nhs.net                 |
| Worcestershire Acute Hospitals NHS Trust             | wah-tr.FOI@nhs.net                 |
| Wye Valley NHS Trus                                  | Freedom.Information@wvt.nhs.uk     |

| <b>Health Board/Organisation</b>          | <b>FOI Contact Details</b>        |
|---|-----------------------------------|
| Aneurin Bevan University Health Board     | FOI.ABB@wales.nhs.uk              |
| Betsi Cadwaladr University Health Board   | bcu.foi@wales.nhs.uk              |
| Cardiff & Vale University Health Board    | FOI.Requests@wales.nhs.uk         |
| Cwm Taf Morgannwg University Health Board | Freedomofinformation@wales.nhs.uk |
| Hywel Dda University Health Board         | FOI.hyweldda@wales.nhs.uk         |
| Swansea Bay University Health Board       | FOIA.Requests@wales.nhs.uk        |
| Velindre University NHS Trust             | Foi.vunhst@wales.nhs.uk           |

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: [www.ico.org.uk/foicomplaints](http://www.ico.org.uk/foicomplaints)

Web site: <https://ico.org.uk/>

### **Re-use of Public Sector Information**

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.


Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



**David Farnsworth**  
**Assistant Director, Community Services Group**



**Claire Madsen**  
**Executive Director of Allied Health Professionals, Health Sciences and Digital**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.